Matthew D. Blunt

830 total citations
31 papers, 606 citations indexed

About

Matthew D. Blunt is a scholar working on Immunology, Genetics and Molecular Biology. According to data from OpenAlex, Matthew D. Blunt has authored 31 papers receiving a total of 606 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Immunology, 14 papers in Genetics and 13 papers in Molecular Biology. Recurrent topics in Matthew D. Blunt's work include Immune Cell Function and Interaction (15 papers), Chronic Lymphocytic Leukemia Research (14 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). Matthew D. Blunt is often cited by papers focused on Immune Cell Function and Interaction (15 papers), Chronic Lymphocytic Leukemia Research (14 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). Matthew D. Blunt collaborates with scholars based in United Kingdom, United States and Australia. Matthew D. Blunt's co-authors include Stephen G. Ward, Salim I. Khakoo, Edward Carter, Francesco Forconi, Andrew J. Steele, Graham Packham, Mark S. Cragg, Jonathan C. Strefford, Marta Larráyoz and Rachel Dobson and has published in prestigious journals such as Blood, The Journal of Immunology and Cancer Research.

In The Last Decade

Matthew D. Blunt

30 papers receiving 602 citations

Peers

Countries citing papers authored by Matthew D. Blunt

Since Specialization

Citations

This map shows the geographic impact of Matthew D. Blunt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew D. Blunt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew D. Blunt more than expected).

Fields of papers citing papers by Matthew D. Blunt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew D. Blunt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew D. Blunt. The network helps show where Matthew D. Blunt may publish in the future.

Co-authorship network of co-authors of Matthew D. Blunt

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew D. Blunt. A scholar is included among the top collaborators of Matthew D. Blunt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew D. Blunt. Matthew D. Blunt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NK Cells in the Lymph Nodes and Their Role in Anti-Tumour Immunity 2024 ·Biomedicines ·(unknown), Salim I. Khakoo, Matthew D. Blunt	4
2	CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis 2024 ·PubMed ·(unknown), (unknown), (unknown), (unknown), (unknown), Russell B. Foxall, (unknown), Kerry L. Cox, Robert Oldham, Martin C. Taylor, Margaret Ashton‐Key, (unknown), (unknown), Ali Roghanian, Eric Eldering, Andrés F. Vallejo, Francesco Forconi, (unknown), Mark S. Cragg, Matthew D. Blunt	0
3	The nuclear export protein XPO1 provides a peptide ligand for natural killer cells 2024 ·Science Advances ·Matthew D. Blunt, (unknown), Ralf B. Schittenhelm, (unknown), (unknown), Sajida Khan, (unknown), (unknown), (unknown), Daniel Burns, (unknown), (unknown), Salah Mansour, Jonathan W. Essex, Rochelle Ayala, Jayajit Das, Anthony W. Purcell, Salim I. Khakoo	2
4	XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression 2023 ·Leukemia ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Peter Johnson, Yosef Landesman, Mark S. Cragg, Francesco Forconi, Christopher J. Walker, Salim I. Khakoo, Matthew D. Blunt	12
5	Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL 2023 ·Leukemia ·(unknown), (unknown), (unknown), (unknown), Jeongmin Woo, Matthew D. Blunt, Francesco Forconi, Freda K. Stevenson, Christopher C. Goodnow, Amanda J. Russell, Peter Humburg, Graham Packham, Andrew J. Steele, Jonathan C. Strefford	2
6	Selinexor Enhances Natural Killer Cell Function Against Multiple Myeloma Cells 2023 ·Blood ·(unknown), (unknown), (unknown), Francesco Forconi, Mark S. Cragg, Christopher J. Walker, Salim I. Khakoo, Matthew D. Blunt	1
7	Harnessing natural killer cell effector function against cancer 2023 ·PubMed ·Matthew D. Blunt, Salim I. Khakoo	7
8	Targeting KIR as a novel approach to improve CAR-NK cell function 2023 ·PubMed ·(unknown), (unknown), Salim I. Khakoo, Matthew D. Blunt	4
9	KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity 2022 ·The Journal of Immunology ·Matthew D. Blunt, Andrés F. Vallejo, (unknown), (unknown), (unknown), (unknown), Matthew Carter, Marta E. Polak, Peter Johnson, Mark S. Cragg, Francesco Forconi, Salim I. Khakoo	9
10	Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E 2021 ·Frontiers in Oncology ·(unknown), Christopher J. Walker, (unknown), Peter Johnson, Francesco Forconi, Mark S. Cragg, Yosef Landesman, Salim I. Khakoo, Matthew D. Blunt	17
11	The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma 2021 ·PubMed ·(unknown), Salim I. Khakoo, Matthew D. Blunt	7
12	Constitutive Activation of Natural Killer Cells in Primary Biliary Cholangitis 2019 ·Frontiers in Immunology ·Theresa Hydes, Matthew D. Blunt, (unknown), Andrés F. Vallejo, Grégory Seumois, Alice Wang, Pandurangan Vijayanand, Marta E. Polak, Salim I. Khakoo	16
13	Regulation and Impact of BCR Induced Autophagy in Chronic Lymphocytic Leukemia 2017 ·Blood ·(unknown), (unknown), Margaret Ashton‐Key, Jonathan C. Strefford, Freda K. Stevenson, Graham Packham, Mark S. Cragg, David A. Tumbarello, Matthew D. Blunt, Francesco Forconi, Andrew J. Steele	1
14	Hydrogen Peroxide Triggers a Dual Signaling Axis To Selectively Suppress Activated Human T Lymphocyte Migration 2017 ·The Journal of Immunology ·Jennifer Ball, Isabella Vlisidou, Matthew D. Blunt, Will Wood, Stephen G. Ward	13
15	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia 2016 ·Clinical Cancer Research ·Matthew D. Blunt, Stefan Koehrer, Rachel Dobson, Marta Larráyoz, (unknown), (unknown), (unknown), (unknown), Andrew Davies, Peter Johnson, Pamela B. Conley, Anjali Pandey, Jonathan C. Strefford, Freda K. Stevenson, Graham Packham, Francesco Forconi, Greg Coffey, Jan A. Burger, Andrew J. Steele	54
16	Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia 2015 ·Leukemia Research Reports ·Matthew D. Blunt, Andrew J. Steele	7
17	The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1 2015 ·Leukemia ·Marta Larráyoz, Stuart J. Blakemore, Rachel Dobson, Matthew D. Blunt, Matthew Rose‐Zerilli, Renata Walewska, Andrew Duncombe, David Oscier, Kazunori Koide, Francesco Forconi, Graham Packham, Minoru Yoshida, Mark S. Cragg, Jonathan C. Strefford, Andrew J. Steele	83
18	Pharmacological Targeting of Phosphoinositide Lipid Kinases and Phosphatases in the Immune System: Success, Disappointment, and New Opportunities 2012 ·Frontiers in Immunology ·Matthew D. Blunt, Stephen G. Ward	14
19	Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies 2012 ·Pharmacological Reviews ·(unknown), Matthew D. Blunt, Edward Carter, Stephen G. Ward	99
20	Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia 2012 ·Current Opinion in Pharmacology ·Matthew D. Blunt, Stephen G. Ward	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact